熱門資訊> 正文
Nanobiotix突出显示放疗后JNJ-1900（NBTXR 3）治疗的中位13.3个月局部无进展生存期
2025-05-05 14:11
- Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer
- Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]
- Median Local Progression-Free Survival of 13.3 months from completion of radiation
- Notable findings observed in exploratory biomarker analyses include:
- An association between increased circulating tumor mutational burden (cTMB) and LPFS and OS
- CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS
- First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy (capecitabine or 5-FU) to radiotherapy-activated JNJ-1900 (NBTXR3) and recruitment is ongoing
- Investigators concluded that these results support further evaluation in a randomized study
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
